Oncology News | pharmaphorum

News

AZ's CEO dismisses "fake news" about his imminent departure

AstraZeneca’s CEO Pascal Soriot has dismissed continued rumours about his departure as “fake news” as the company announced full year results showing sales growth for the first time in a de

News

Packaged Pills in aluminium blisters stacked on each other

Clinigen buys remaining rights to Novartis cancer drug

UK pharma Clinigen is to buy the remaining rights to Novartis’ cancer drug Proleukin, in a deal worth up to $210 million.

News

Merck's Keytruda gets boost in kidney and head and neck canc...

Merck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Bristol-Myers Squibb, with positive results in kidney cancer, and the promise of an F

News

Grey Wolf raises £10m for tumour 'illumination' tech

Immuno-oncology biotech Grey Wolf Therapeutics has raised £10 million in series A financing to develop therapies that increase tumour visibility.

News

T-cells attacking cancer cell illustration of microscopic photos

‘Trojan horse’ cancer drug shows promise in multiple tumour ...

A new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.

News

Daiichi gets speedy FDA review for rare cancer drug

Daiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become the first systemic drug therapy for rare cancer tenosynovial giant cell tumour (TGCT).

AZ's CEO dismisses "fake news" about his imminent departure

Clinigen buys remaining rights to Novartis cancer drug

Merck's Keytruda gets boost in kidney and head and neck canc...

Grey Wolf raises £10m for tumour 'illumination' tech

‘Trojan horse’ cancer drug shows promise in multiple tumour ...

Daiichi gets speedy FDA review for rare cancer drug

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks